Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401
These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results - Lantheus Holdings (NASDAQ:LNTH